Teva Pharma (TEVA) PT Raised to $26 at UBS, 2030 Sales Estimate Increased
Tweet Send to a Friend
UBS analyst Ashwani Verma raised the price target on Teva Pharma (NYSE: TEVA) to $26.00 (from $23.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
